Data highlights symptom stability and enhanced efficacy signals in higher dose group –– Analysis offers valuable insights to guide ongoing ...

Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced the launch of "Power in the Periphery," a new disease education ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

ATH434 improves daily function and reduces brain iron in patients with multiple system atrophy, a rare, fatal ...

Alterity Therapeutics’ phase II study of its lead compound ATH434 in multiple system atrophy (MSA) has been featured in an ...

An update from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics presented promising data on ATH434 at the 36th ...

"Multiple System Atrophy Competitive Landscape"Multiple System Atrophy companies are Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM ...

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development. New ...

DUBLIN, Aug. 25, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), today announced completion of enrollment in the open-label portion of its ...